|
|
 Previous Article | Table of Contents | Next Article 
HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34+ Early Progenitor Cells
Tuna Mutis,
Ellen Schrama,
Simone A.P. van Luxemburg-Heijs,
J.H.F Falkenburg,
Cornelis J.M. Melief, and
Els Goulmy
From the Departments of Immunohematology and Blood Bank, and Haematology, Leiden University Hospital, Leiden, The Netherlands.
After allogeneic bone marrow transplantation (BMT), the beneficial graft-versus-leukemia (GVL) effect but also the life-threatening graft-versus-host disease (GVHD) are mediated by T cells of the grafted marrow. The identification of leukemia cell-reactive T cells and their ligands are, therefore, crucial for the development of new anti leukemia strategies. Here we describe a leukemia-reactive allo-HLA class II restricted CD4+ T-cell clone, 6.2, isolated from a healthy individual after stimulation with allogeneic leukemic cells. Clone 6.2 recognizes leukemic cells from several AML patients without showing reactivity to unfractioned peripheral blood mononuclear cells, monocytes, B cells, T-cell blasts, and proximal tubulus epithelial cells. Interestingly, clone 6.2 also recognizes BM cells derived from healthy individuals and inhibits the colony formation of myeloid and erythroid cell lineages. In the BM, clone 6.2 recognizes only CD34+ early precursor cells but not CD34-, more differentiated cells. Thus, the target antigen of clone 6.2 is developmentally regulated and expressed only by leukemic cells and CD34+ early progenitor cells in the hematopoietic system. We suggest that targeting the T-cell immune response to leukemia-associated, developmentally regulated antigens of the hematopoietic system can provide a basis for the separation of GVL from GVHD, and may lead to new therapeutic approaches for residual and relapsed leukemia.
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 1083-1090
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Guimond, A. Balassy, M. Barrette, S. Brochu, C. Perreault, and D. C. Roy
P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells
Blood,
June 28, 2002;
100(2):
375 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Mutis, E. Blokland, M. Kester, E. Schrama, and E. Goulmy
Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation
Blood,
June 28, 2002;
100(2):
547 - 552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lokhorst, A. Schattenberg, J. J. Cornelissen, M. H. J. van Oers, W. Fibbe, I. Russell, N. W. C. J. v. d. Donk, and L. F. Verdonck
Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome
J. Clin. Oncol.,
August 16, 2000;
18(16):
3031 - 3037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Costello, F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J.-A. Gastaut, and D. Olive
Human Acute Myeloid Leukemia CD34+/CD38- Progenitor Cells Have Decreased Sensitivity to Chemotherapy and Fas-induced Apoptosis, Reduced Immunogenicity, and Impaired Dendritic Cell Transformation Capacities
Cancer Res.,
August 1, 2000;
60(16):
4403 - 4411.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Brenner, C. Rossig, U. Sili, J. W. Young, and E. Goulmy
Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy
Hematology,
January 1, 2000;
2000(1):
356 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.H. F. Falkenburg, A. R. Wafelman, P. Joosten, W. M. Smit, C. A.M. van Bergen, R. Bongaerts, E. Lurvink, M. van der Hoorn, P. Kluck, J. E. Landegent, et al.
Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes
Blood,
August 15, 1999;
94(4):
1201 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Li, S. A. Furman, C. R. Bradford, and A. E. Chang
Expanded Tumor-reactive CD4+ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation
Clin. Cancer Res.,
February 1, 1999;
5(2):
461 - 469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Mutis, E. Schrama, C. J.M. Melief, and E. Goulmy
CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens
Blood,
September 1, 1998;
92(5):
1677 - 1684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
